Sodium channel alpha subunit · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Sodium channel alpha subunit shows approved-linked disease relevance led by epilepsy. 5 more disease programs remain visible in the same review block. 16 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P35498. Start with epilepsy, then reuse UniProt P35498 as the stable protein anchor across project notes and exports.
Start with epilepsy, then reuse UniProt P35498 as the stable protein anchor across project notes and exports.
Sodium channel alpha subunit shows approved-linked disease relevance led by epilepsy. 5 more disease programs remain visible in the same review block. 16 linked drugs remain visible in the same block.
Start review with epilepsy because it currently carries approved-linked support. Linked drugs include CARBAMAZEPINE, CENOBAMATE, ESLICARBAZEPINE, ESLICARBAZEPINE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxySodium channel protein type 1 subunit alpha
Review this target as Sodium channel alpha subunit, mapped to UniProt P35498. ChEMBL maps the protein component as Sodium channel protein type 1 subunit alpha. Sequence length is 2009 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sodium channel alpha subunit as ChEMBL target CHEMBL2331043, mapped to UniProt P35498. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Sodium channel alpha subunit is the right protein anchor across sources, using UniProt P35498 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why epilepsy is currently framed as approved-linked support. It currently carries 16 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Sodium channel alpha subunit |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P35498 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Sodium channel protein type 1 subunit alpha |
| UniProt Accession | P35498 |
| Component Type | Protein |
| Sequence Length | 2009 aa |
Sodium channel protein type 1 subunit alpha
Review this target as Sodium channel alpha subunit, mapped to UniProt P35498. ChEMBL maps the protein component as Sodium channel protein type 1 subunit alpha. Sequence length is 2009 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Sodium channel alpha subunit shows approved-linked disease relevance led by epilepsy. 5 more disease programs remain visible in the same review block.
Start review with epilepsy because it currently carries approved-linked support. Linked drugs include CARBAMAZEPINE, CENOBAMATE, ESLICARBAZEPINE, ESLICARBAZEPINE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL1423 | 7.27 | IC50 | 54.0 | Approved |
| CHEMBL45816 | 6.01 | IC50 | 980.0 | Approved |
| CHEMBL12713 | 5.64 | IC50 | 2300.0 | Approved |
| CHEMBL11 | 5.44 | IC50 | 3600.0 | Approved |
| CHEMBL71 | 5.37 | IC50 | 4300.0 | Approved |
| CHEMBL633 | 5.32 | IC50 | 4800.0 | Approved |
| CHEMBL54 | 5.16 | IC50 | 7000.0 | Approved |
| CHEMBL87045 | 5.11 | IC50 | 7800.0 | Clinical |
| CHEMBL5314404 | 5.09 | IC50 | 8200.0 | Clinical |
| CHEMBL23 | 5.05 | IC50 | 9000.0 | Approved |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 16 | 16 | 5.2 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein format | 11 | 0 | — |